检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:邵静茹 顾艳[2] 刘艳[1] 潘英芳 聂向民[1] 李文超[1] SHAO Jingru;GU Yan;LIU Yan;PAN Yingfang;NIE Xiangmin;LI Wenchao(Blood Center of Shandong Province,Jinan 250000,China;Department of Pediatrics,First Affiliated Hospital of Shandong First Medical University&Shandong Provincial Qianfoshan Hospital,Shandong Engineering and Technology Research Center for Pediatric Drug Development,Jinan 250000,China)
机构地区:[1]山东省血液中心,济南250000 [2]山东第一医科大学第一附属医院(山东省千佛山医院)小儿内科、山东省儿童药物临床评价与研发工程技术研究中心,济南250000
出 处:《免疫学杂志》2024年第9期739-742,共4页Immunological Journal
基 金:山东省医药卫生科技发展计划(202302071062);山东省医务系统职工创新计划(SDYWZGKCJH2022087)。
摘 要:目的通过调查山东地区有妊娠史的女性献血者HLA-I、HLA-II类抗体阳性发生率,探讨HLA抗体检测对降低临床血小板输血不良反应的意义,同时为安全输血、合理使用血液制品提供数据支持。方法使用流式细胞仪-微珠法,对纳入本次研究的186份样本进行HLA-I和HLA-II抗体的检测。结果186名有妊娠史的女性献血者中,检测出HLA-I类抗体阳性者77例(阳性率41.4%),HLA-II体阳性者41例(阳性率22.0%),HLA-I类和HLA-II类抗体阳性者共计92例(阳性率49.5%)。结论初步调查了本地区有妊娠史的女性献血者HLA抗体分布情况,其HLA抗体阳性率高达49.5%。本研究的结果对如何合理利用血液制品和HLA抗体引起的输血免疫相关并发症预防措施的建立提供了一定的数据基础。Objective To investigate the positive rate of HLA-I or/and HLA-II antibody in female blood donors with a history of pregnancy in Shandong region,with an aim of exploring the significance of HLA antibody testing in reducing clinical platelet transfusion adverse reactions,and providing data support for safe blood transfusion and rational use of blood products.Method Flow cytometry microbead method was used to detect HLA-I and HLA-II antibodies in 186 samples included in this study.Result Among 186 female blood donors with pregnancy history,77 were detected as positive for HLA-I class antibodies(41.4%),41 cases were HLA-II positive(22.0%),92 cases were positive for HLA-I or/and HLA-II antibodies(49.5%).Conclusion A preliminary investigation has conducted on the distribution of HLA antibodies among female blood donors with a history of pregnancy in the local area,and the HLA antibody positivity rate is as high as 49.5%.The results of this study provide a certain data basis for the establishment of preventive measures for transfusion immune related complications caused by blood products and HLA antibodies in a reasonable manner.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:3.136.17.231